The Study Of Ulinastatin Used In Infant Critical Congenital Heart Disease During Perioperative

Objective: To study the regulation action of Ulinastatin to inflammatory response used in infant critical congenital heart disease during perioperation.Methods: Thirty infants with critical congenital heart disease who were younger than six months and with surgical indications were randomly allocated into two groups. IncluSion criteria :Tetralogy of Fallot,Total anomalous pulmonary venous drainage ,Transposition of the great vessels,Atrioventricular septal defect,Ventricular septal defect with pulmonary hypertension, coarctation of aorta with inner-heart malformation. Study group(n = 15):beside of giving regular treatment ,give Ulinastatin 5ooou/kg.t and eight hours/times and continuous three days. Control group (n = 15):Only giving regular treatment. Age, weight, aortic cross-clamp time, cardiopulmonary bypass (CPB) time, mechanical ventilation time, intensive care time and post-operative hospitalization time and other clinical indicators were monitored . The plasma interleukin-6(IL-6),IL-10,Tumor necrosis factor(TNF-a) and troponin I (cTnI) were measured at postoperative 1h,6h,24h,48h,72h in both groups.Results: The Age, weight, aortic cross-clamp time, CPB time, mechanical ventilation time, intensive care time and post-operative hospitalization time of two groups'infants have no significant difference(P>0.05),but compared with control group, the concentration of postoperative cTnI,IL-6,TNF-a in study group reduced earlier and more obvious ,Study group were significantly lower than control group in time of T5(P<0.05).However,decreased levels of IL-10 was just on the contrary, study group decreased slower and study group higher than the control group significantly in time of T5(P<0.05).Conclusions: Ulinastatin used in infant critical congenital heart disease during perioperative can restrain inflammatory response ,reduce tissue injury and benefit myocardial tissue has been injured to recover earlier.